Myeloproliferative neoplasms (MPNs) are a group of closely related hematologic malignancies that arise from abnormal development and function of the body’s bone marrow cells. Primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocythemia (ET) comprise the Philadel phia chromosome (Ph)-negative MPNs.1 Myelofibrosis (MF) can arise on its own, which is called PMF, or it can result from the progression of other MPNs, such as postpolycythemia vera MF (PPVMF) and postessential throm bocythemia MF (PET-MF).1 Read More ›
CHICAGO—Treatments for multiple myeloma have advanced rapidly over the past 15 years as research has fostered an improved understanding of the mechanisms of the disease. These discoveries have been translated into effective drugs, most notably bortezomib, thalidomide, and lenalidomide.
CHICAGO—Decitabine extends overall survival and improves response rates compared with standard therapies in the treatment of older patients with newly diagnosed acute myelogenous leukemia (AML), said Xavier G. Thomas, MD, PhD.
The treatment options for older patients with AML are limited. Intensive chemotherapy is generally poorly tolerated in this group, the initial mortality rate is high (exceeding 30% at 8 weeks), the response rate to chemotherapy is poor, and relapse rates are high.
Case Presentation
Chief complaint: Generalized arthralgia for 5 months.
A combination of fludarabine, pixantrone, dexamethasone, and rituximab (FPD-R) achieved major durable responses in patients with relapsed or refractory indolent non-Hodgkin lymphoma (NHL) in a single-arm phase 1 dose-escalation study. The study identified a dose of 120 mg/m2pixantrone as the recommended dose for this regimen. The overall response rate with this regimen was 89%, and the regimen was well tolerated with no grade 3/4 cardiovascular adverse events. Grade 3/4 lymphopenia occurred, however, in 89% of patients and leukopenia in 79%.
Patients with acute myeloid leukemia (AML) receive unnecessarily high-dose levels of chemotherapy, according to Dr Bob Löwenberg, professor of Hematology at the Erasmus University Medical Center in Rotterdam, The Netherlands at the 16th Congress of the European Hematology Association.
Read More ›
To sign up for our newsletter or print publications, please enter your contact information below.